The genus Cardiovirus belongs to the family Picornaviridae of positive-sense ssRNA viruses. Currently, two cardiovirus species are recognized -encephalomyocarditis virus (EMCV) (including mengovirus) and Theilovirus. The latter species encompasses a number of divergent clades and isolates, including Theiler's murine encephalomyelitis virus (TMEV), Thera virus, Vilyuisk human encephalomyelitis virus and human Saffold viruses. The cardiovirus genome comprises a single RNA molecule of~8 kb that contains a single long ORF, which is translated as two polyproteins each of which is cleaved by the virus-encoded 3C protease (Palmenberg et al., 1984; Jackson, 1986; Palmenberg, 1990) . Like many picornaviruses, cardioviruses use an unusual proteolysis-independent but ribosome-dependent mechanism, termed 'StopGo' or 'Stop-Carry on', to release the [L-1ABCD-2A] polyprotein from the ribosome and to specify the N-terminal amino acid of the polyprotein (Batson & Rundell, 1991; Palmenberg et al., 1992; Atkins et al., 2007; Brown & Ryan, 2010) . The Cterminal amino acid of the [L-1ABCD-2A] polyprotein and the N-terminal amino acid of the [2BC-3ABCD] polyprotein are encoded by adjacent codons -no stop codon or proteolytic processing is involved. StopGo is mediated by a highly conserved amino acid motif -D(V/I)ExNPG Q Pwhich, together with upstream amino acids that have a strong a-helical propensity, prevents formation of a peptide bond between Asn-Pro-Gly and Pro, but allows the continuation of translation with up to near-100 % efficiency (Ryan & Drew, 1994; Hahn & Palmenberg, 1996; Donnelly et al., 1997; Hahn & Palmenberg, 2001; Donnelly et al., 2001a; Doronina et al., 2008; Brown & Ryan, 2010) . (Roos et al., 1989; Batson & Rundell, 1991; Palmenberg et al., 1992) . Mutational analysis indicated that the highly conserved -NPGP-motif is indispensable for StopGo activity (Hahn & Palmenberg, 1996; Donnelly et al., 2001b) . Hahn & Palmenberg (1996) also determined a critical role for StopGo activity for normal viral infection. In that study, HeLa monolayers infected with StopGo-mutated EMCV failed to form plaques.
To establish whether a general requirement for StopGo activity exists in other cardiovirus species/clades and in an aphthovirus species, we set out to investigate the effects of StopGo mutations in TMEV and foot-and-mouth disease virus (FMDV) on virus viability and polyprotein processing. Although there are no previous reports describing mutations engineered within the TMEV StopGo motif, an -NPGP-to -NAGP-mutation (PA mutation) has been shown to inhibit FMDV StopGo activity using a reporter system (Donnelly et al., 2001b) . However, mutation of a proline codon (CCX) to an alanine codon (GCX) necessarily requires only a single base change; therefore, to reduce the possibility of reversion, we made a second StopGo mutation, -NPGP-to -NPLV-(LV mutation) that would require at least four base changes for complete reversion. To determine whether these StopGo mutations can disable TMEV StopGo activity, mutations were first introduced into partial virus cDNA subclones encoding 1D2A2B and part of 2C (1D2A2B2Cmid) (Fig. 1a) . This sequence is devoid of other virus processing events (in particular cleavage by 3C protease). StopGo mutations (PA and LV) to 1D2A2B2Cmid were engineered by a standard two-step PCR (Phusion polymerase; NEB) using primers 1-6 (Table S1 , available in JGV Online), with pSK-GDVII as template. pSK-GDVII is a full-length infectious cDNA clone of TMEV [virus GDVII (GenBank accession no. NC_001366) is a virulent strain of TMEV]. As a control, we also mutated mengovirus -NPGP-to -NPLV-(LV mutation) in the context of 1D2A2B2Cmid by two-step PCR (primers 7-10, Table S1), with mengovirus cDNA (pMC0) as template. pMC0 is a full-length infectious recombinant mengovirus (vMC0) identical to GenBank accession no. DQ294633 except in the 59UTR where vMC0 has the poly(C) tract deleted (Duke et al., 1990) . All amplicons were cloned BamHI/XbaI into pcDNA3.1 (Invitrogen) using standard cloning procedures, and all clones were confirmed by sequencing.
DNA encoding wild-type and StopGo-mutated TMEV and mengovirus 1D2A2B2Cmid were used to programme coupled in vitro transcription-translation reactions in rabbit reticulocyte extracts with [
35 S] methionine according to the manufacturer's (Promega) instructions (Fig. 1b) . As expected for translation of a functional StopGo, both TMEV and mengovirus wild-type constructs expressed 1D2A and 2B2Cmid as separate proteins (Fig. 1b) . All StopGo-mutated constructs expressed a 1D2A2B2Cmid fusion, indicating that these mutations (PA and LV) disable StopGo activity. Densitometry (ImageQuant) of radiolabelled 1D2A and 2B2Cmid and normalization for encoded methionines, indicated that, as previously reported for FMDV (Donnelly et al., 2001a) , active StopGo results in an equimolar ratio of N-and C-terminal products. Together, these results show that in TMEV, mutating the highly conserved StopGo motif completely inhibits StopGo activity, which is in complete agreement with previous in vitro StopGo mutagenesis studies in FMDV (Donnelly et al., 2001a) and EMCV (Hahn & Palmenberg, 1996) .
We next set out to determine the effect that disabling StopGo might have on virus viability and polyprotein processing by replicating these mutations in the context of full-length virus. Recombinant TMEV genomes containing mutations in the StopGo motif were made by subcloning the AccIII/BsgI region of the mutant TMEV 1D2A2B2Cmid cDNAs into pSK-GDVII. Similarly, mutant mengovirus genomes were engineered by subcloning the BglII/AflII region of the mutant mengovirus 1D2A2B2Cmid cDNAs into pMC0. In addition, a full-length infectious FMDV cDNA clone, A24 Cruzeiro, [pA24-WT (Rieder et al., 2005) ] was used to derive A24-PA and A24-LV mutant RNAs by two-step PCR by using primers 13-16 (Table S1 ). PCR amplicons were digested with SnaBI/MfeI and cloned into pA24-WT digested with the same enzymes. Again standard cloning procedures were used throughout, and all clones were confirmed by sequencing.
Plasmids encoding full-length wild-type and StopGomutated infectious TMEV, FMDV and mengovirus cDNAs were linearized with either XbaI (TMEV), SwaI (FMDV) or BamHI (mengovirus) and transcribed with T7 RNA polymerase (Megascript; Ambion) for 3 h at 37 u C. Equivalent amounts of RNA (TMEV and mengovirus) were transfected into BHK-21 cells (ATCC) using DMRIE-C (Invitrogen) according to the manufacturer's recommendations. BHK-21 cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10 % FBS, 1 mM L-glutamine and antibiotics and incubated at 37 u C with 5 % CO 2 . Twenty-four hours after transfection, virus titres were quantified by plaque assay. Transfected cells were subjected to three freeze-thaw cycles followed by centrifugation (1800 g) to pellet cell debris. Supernatants were collected then aliquoted and stored at 280 u C. BHK-21 monolayers (90 % confluent) were infected with 10-fold dilutions of each supernatant for 1 h at 37 u C. The virus inocula were removed, and cells overlaid with 1.0 % agarose containing MEM. After 48 h incubation (72 h for mengovirus-LV) at 37 uC, cells were fixed with 2.5 % formalin, and plaques visualized by crystal violet staining. Surprisingly, even though we fully expected inhibition of StopGo activity with the two TMEV mutants (PA and LV), virus titres were similar to wild-type, whereas we observed at least a 3 log decrease in virus titre between wild-type and StopGoinactivated mengovirus (Fig. 2a) . One-step growth curves comparing wild-type and mutant TMEV showed little difference (Fig. 2b) . For one-step growth curves, BHK-21 monolayers were infected as above at an m.o.i. of 1.0 and then infected cells collected and viruses recovered by freezethawing 6, 12 and 24 h post-infection. Virus titres from each time point were determined by plaque assay. To rule out the possibility that these surprising results for TMEV could be explained by reversion or contamination, RNA was extracted from 200 ml of each virus stock using the Trizol (Invitrogen) method, then reverse transcribed (Superscript III; Invitrogen) with primer 2 (Table S1 ). The sequence surrounding the 2A-2B junction was amplified by PCR using primers 11 and 12 (Table S1 ) and amplicons sequenced on both strands to confirm that reversion had not occurred. For FMDV, electroporation was used to transfect BHK-21 cells as described previously (Rieder et al., 1993) . Blind passages were carried out resulting in the absence of cytopathic effects (CPE). Therefore, StopGomutated FMDV produced no viable progeny even after several passages (Fig. 2c ).
While we clearly observed StopGo inhibition by in vitro translation experiments (Figs 1b and 3b ), replicating these same mutations into the full-length infectious cDNAs resulted in stark differences between TMEV, FMDV and mengovirus. Again consistent with a previous report in which StopGo was mutated in EMCV (Hahn & Palmenberg, 1996) , StopGo-mutated mengovirus was severely attenuated (Fig. 2a) . This contrasted dramatically with StopGo-mutated TMEV, which appeared completely normal under the conditions tested (Fig. 2a, b ).
Although we observed little effect of inhibiting StopGo on TMEV in cultured cells, we next tested the possibility that the mutant TMEV may lose virulence in a more natural setting (in vivo). Rodents are the natural host of TMEV, and intracerebral GDVII virus infections of mice cause acute and fatal encephalitis (Villarreal et al., 2006) . We injected intracerebrally 1000 p.f.u. of wild-type and LV mutant TMEV into SJL/J mice (13 animals for each group) and then monitored the number of days post-injection for death to occur. All mice injected with wild-type or StopGomutated TMEV were dead by the end of day 7 at the expected time (Table S2 ), indicating that these mutant viruses were completely viable even though they did not have StopGo activity.
Since inactivating StopGo in TMEV does not affect viral infectivity or replication in BHK-21 cells, we were able to monitor the effect of disrupting StopGo on TMEV polyprotein processing by pulse-labelling. BHK-21 cells (90-100 % confluent) in 35 mm dishes were infected with wild-type or mutant TMEV (m.o.i. 10). After 60 min of adsorption at 37 u C, the virus inocula were removed. The cells were washed once with methionine-free DMEM and incubated in 0.25 ml methionine-free DMEM. Cells were labelled with [
35 S] methionine (50 mCi ml
21
) at 37 u C for 30 min, washed once in PBS, lysed by suspension in 0.2 ml of sample buffer and heated at 95 u C for 5 min. Lysates were then analysed by SDS-PAGE. After electrophoresis, gels were processed for fluorography with Amplify (Amersham) before drying and exposure to a phosphorscreen. Mutating TMEV StopGo in the context of full-length infectious clones would be expected to produce 2A-2B fusion proteins of~34 kDa. However, as shown in Fig. 3(a) , there was no~34 kDa 2A-2B fusion protein detected in cells infected with mutant TMEV. Instead, a protein very similar in molecular mass to wild-type 2A (~16 kDa) was detected (2A* in Fig. 3a) . Furthermore, unlike polyprotein processing in StopGo-mutated EMCV (Hahn & Palmenberg, 1996) where the P1 proteins were not properly processed, processing of the TMEV P1 proteins appears to be unaffected when StopGo is mutated. The effect of mutating FMDV StopGo was determined by in vitro transcription and translation of FMDV cDNAs and indicates that, as expected, polyprotein processing is severely impaired when StopGo is mutated (Fig. 3b) .
One possible explanation for these unexpected TMEV polyprotein processing data could be that phylogenetically conserved Gln and Gly residues just 9 aa downstream of the StopGo site may act as a cryptic 3C protease cleavage site. In general, the consensus picornavirus 3C cleavage site is hydrophobic-x-x-Q/(G, A or S) (Leong et al., 2002) , and in TMEV and EMCV, the putative cryptic 3C cleavage sites are FQPQ/G and FQTQ/G, respectively. No consensus 3C protease cleavage site exists in this region of FMDV. Therefore, TMEV and EMCV with StopGo mutated would synthesize 2A fused to 2B and subsequent 3C cleavage at the cryptic site would leave the N-terminal 9 aa of 2B still fused to 2A (2A*). The absence of 2A* in the absence of 3C protease (Fig. 1b) also supports this explanation. The possibility of an EMCV cryptic 3C cleavage site near this position has been suggested previously in several other reports (Parks & Palmenberg, 1987; Palmenberg et al., 1992) . Furthermore, in vitro translation of StopGo-mutated EMCV RNA still appeared to synthesize L-P1-2A (Hahn & Palmenberg, 1996) . These authors also failed to detect ã 34 kDa 2A-2B fusion protein during polyprotein processing of StopGo-mutated EMCV. In this regard it is interesting to note that in hepatoviruses the equivalent primary cleavage in this region of the polyprotein (between 2A and 2B) is mediated by the 3C protease (Harmon et al., 1992) .
Another possible explanation for the observed heavier 2A species (2A* in Fig. 3a) when StopGo is mutated could be that it is a 2A-2B* fusion. 2B* is a recently identified transframe protein (Loughran et al., 2011) that is a fusion resulting from a programmed 21 frameshift into a conserved overlapping ORF within the 2B region of EMCV. The conserved EMCV ribosome slip site (G GUU UUY) is also conserved in TMEV and all other cardioviruses. While 2B* in EMCV is~130 aa it is only predicted to encode 11 aa in TMEV. While this possibility might explain the greater mass of 2A in cells infected with the mutant TMEV, it does not adequately explain the absence of the~34 kDa protein (unless fusion of 2B has a dramatic protein destabilizing effect), which would still be expected regardless of frameshifting.
Why does mutating StopGo have such dramatic differences on virus viability between TMEV and mengovirus? One clue is the major difference that mutating StopGo has on polyprotein processing. As can be seen in Fig. 3(a) , polyprotein processing appears identical in the P1 region between TMEV wild-type and mutant viruses. This is in contrast to in vitro translation of StopGo-mutated EMCV RNA where polyprotein processing of the L-P1-2A precursor by 3C protease was impaired, suggesting a critical role for a primary 'cleavage' event to allow proper folding of the P1 precursor in a manner that is compatible with efficient 3C cleavage (Hahn & Palmenberg, 1996) . Consistent with this hypothesis, one of the EMCV mutations made by Hahn and Palmenberg, in which the wild-type -DIETNPGP-was mutated to -DIEvNPGP-, was completely efficient at StopGo but was still unable to properly process the P1 proteins.
StopGo is extremely highly conserved (Luke et al., 2008) . It is unclear to us at this stage why StopGo appears to be dispensable in TMEV, but not in EMCV or FMDV. It seems likely that we simply have not found those conditions in which StopGo provides a clear advantage for TMEV.
